DE60133585D1 - Membran penetrierende peptide und deren anwendungen - Google Patents

Membran penetrierende peptide und deren anwendungen

Info

Publication number
DE60133585D1
DE60133585D1 DE60133585T DE60133585T DE60133585D1 DE 60133585 D1 DE60133585 D1 DE 60133585D1 DE 60133585 T DE60133585 T DE 60133585T DE 60133585 T DE60133585 T DE 60133585T DE 60133585 D1 DE60133585 D1 DE 60133585D1
Authority
DE
Germany
Prior art keywords
applications
penetrating peptides
membrane penetrating
membrane
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60133585T
Other languages
English (en)
Other versions
DE60133585T2 (de
Inventor
Yong Guo
Clarence C Morse
Zhengbin Yao
George A Keesler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Priority claimed from PCT/US2001/026421 external-priority patent/WO2002018572A2/en
Application granted granted Critical
Publication of DE60133585D1 publication Critical patent/DE60133585D1/de
Publication of DE60133585T2 publication Critical patent/DE60133585T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
DE60133585T 2000-08-25 2001-08-23 Membran penetrierende peptide und deren anwendungen Expired - Fee Related DE60133585T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
US227647P 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0103110 2001-02-07
PCT/US2001/026421 WO2002018572A2 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof

Publications (2)

Publication Number Publication Date
DE60133585D1 true DE60133585D1 (de) 2008-05-21
DE60133585T2 DE60133585T2 (de) 2009-06-04

Family

ID=22853919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60133585T Expired - Fee Related DE60133585T2 (de) 2000-08-25 2001-08-23 Membran penetrierende peptide und deren anwendungen

Country Status (10)

Country Link
US (2) US20030229202A1 (de)
JP (1) JP4896356B2 (de)
KR (1) KR100810927B1 (de)
AR (1) AR033834A1 (de)
BR (1) BRPI0113477B8 (de)
DE (1) DE60133585T2 (de)
GB (1) GB0103110D0 (de)
IL (1) IL154589A (de)
TW (1) TWI317737B (de)
ZA (1) ZA200301476B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
US20060008464A1 (en) * 2002-04-08 2006-01-12 Chaim Gilon Histone conjugates and uses thereof
EP1644048B1 (de) 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
EP1631306A4 (de) * 2003-05-19 2009-08-12 Univ Columbia Zusammensetzungen und verfahren zur behandlung und prävention von herzgewebedegeneration und ihre verwendung
EP1740600A4 (de) * 2004-04-13 2009-01-07 Medtronic Sofamor Danek Inc Intrazelluläre zuführung von osteoinduktiven proteinen und peptiden
CA2660661A1 (en) * 2005-09-26 2007-04-05 The Trustees Of Columbia University In The City Of New York Side population cells in cardiac repair
KR20080084937A (ko) * 2005-11-04 2008-09-22 포휴먼텍(주) 융합 폴리펩타이드를 세포로 전달하는 방법
WO2008015580A2 (en) * 2006-07-24 2008-02-07 Forhumantech. Co., Ltd. Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same
KR100843634B1 (ko) * 2006-08-03 2008-07-03 연세대학교 산학협력단 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
WO2009093692A1 (ja) * 2008-01-25 2009-07-30 Toagosei Co., Ltd. 人工ペプチド及びその利用
AU2009215426B2 (en) * 2008-02-21 2015-06-11 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with C-terminal elements
JP5709013B2 (ja) 2009-04-10 2015-04-30 東亞合成株式会社 神経分化誘導ペプチド及びその利用
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
CN102869384B (zh) * 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
JP5858284B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメントとその利用
WO2011013700A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
JP5858283B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
WO2011052679A1 (ja) 2009-11-02 2011-05-05 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
JP5808082B2 (ja) * 2010-04-30 2015-11-10 株式会社Adeka 細胞への水溶性高分子量物質の導入方法及び導入剤
WO2011148996A1 (ja) * 2010-05-25 2011-12-01 国立大学法人熊本大学 物質導入用液体培地及び細胞内への物質導入方法
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
EP2578224B1 (de) 2010-06-04 2017-11-22 Toagosei Co., Ltd. Zellwachstumförderndes peptid und verwendung davon
JP6202707B2 (ja) * 2011-10-13 2017-09-27 国立大学法人鳥取大学 新規細胞膜透過ペプチド
JP6066222B2 (ja) 2012-05-28 2017-01-25 東亞合成株式会社 抗菌ペプチド及びその利用
US20150104873A1 (en) * 2012-07-11 2015-04-16 University of Nevada, Las Vegas Genome Surgery with Paired, Permeant Endonuclease Construct
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
US20150353959A1 (en) * 2013-01-18 2015-12-10 Glycotope Gmbh Peptides for enhancing protein expression
SG11201604697TA (en) 2013-12-12 2016-07-28 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016136708A1 (ja) 2015-02-27 2016-09-01 学校法人常翔学園 膜透過性ペプチドを側鎖に有する高分子化合物
WO2016136707A1 (ja) 2015-02-27 2016-09-01 学校法人常翔学園 膜透過性ペプチド鎖を有する多糖誘導体
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
SG11201912071QA (en) 2017-06-22 2020-01-30 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
US20210087231A1 (en) * 2018-02-06 2021-03-25 University Of Maryland, Baltimore Tlr9 inhibitors to suppress inflammatory response to pathogens
US20220009968A1 (en) * 2018-12-27 2022-01-13 Industry-University Cooperation Foundation Hanyang University Crispr-cas-based composition for gene correction
KR102386498B1 (ko) * 2018-12-27 2022-04-15 한양대학교 산학협력단 Crispr-cas를 기반으로 하는 유전자 교정용 조성물
CA3176021A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CN110441156A (zh) * 2019-07-20 2019-11-12 大连理工大学 一种基于土体稳定状态特性测量三轴试样膜嵌入量的方法
CN114716569B (zh) * 2022-04-13 2023-11-10 浙江大学 一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6197925B1 (en) * 1991-08-22 2001-03-06 Sara Lee Corporation NF-AT polypeptides and polynucleotides
US5843643A (en) * 1992-02-21 1998-12-01 Ratner; Paul L. Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6235521B1 (en) * 1996-08-09 2001-05-22 Dnavec Research Phage bonded to a nuclear location signal
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US5962415A (en) 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
US5929042A (en) * 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof
WO1998049325A1 (en) 1997-04-28 1998-11-05 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
US6436628B1 (en) * 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
EP1117720A4 (de) * 1998-07-13 2001-11-14 Expression Genetics Inc Poly-l-lysin analoge polyester als lösliche bioabbaubare gentransferträger
US6246558B1 (en) * 1998-08-24 2001-06-12 Leviton Manufacturing Company Circuit interrupting device with reverse wiring protection
FR2786397B1 (fr) 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
CA2375450C (en) * 1999-06-08 2009-04-28 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins
AU785007B2 (en) 1999-11-24 2006-08-24 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
JP3908425B2 (ja) * 1999-12-24 2007-04-25 アルパイン株式会社 ナビゲーション装置
WO2001093836A2 (en) 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes
JP3686961B2 (ja) * 2000-08-04 2005-08-24 シャープ株式会社 液晶表示装置及びそれを用いた電子機器
JP2002304088A (ja) * 2001-04-09 2002-10-18 Ricoh Co Ltd 画像形成装置
WO2003064609A2 (en) * 2002-01-29 2003-08-07 Aventis Pasteur, Ltd. Targeted immunogens
US6877262B2 (en) * 2003-07-10 2005-04-12 Ronald Bianco Perpetual calendar
DE10341112A1 (de) * 2003-09-05 2005-03-31 Li-Li Yehhsu Behälter mit separaten Speicherkammern
WO2005066203A2 (en) * 2003-12-31 2005-07-21 Sanofi Pasteur, Inc. Targeted immunogens

Also Published As

Publication number Publication date
DE60133585T2 (de) 2009-06-04
GB0103110D0 (en) 2001-03-28
US20060100134A1 (en) 2006-05-11
KR20030034156A (ko) 2003-05-01
US7754678B2 (en) 2010-07-13
BRPI0113477B8 (pt) 2021-05-25
KR100810927B1 (ko) 2008-03-10
ZA200301476B (en) 2004-06-22
JP2004512275A (ja) 2004-04-22
JP4896356B2 (ja) 2012-03-14
BRPI0113477B1 (pt) 2019-10-22
TWI317737B (en) 2009-12-01
AR033834A1 (es) 2004-01-07
US20030229202A1 (en) 2003-12-11
BR0113477A (pt) 2004-04-20
IL154589A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
DE60133585D1 (de) Membran penetrierende peptide und deren anwendungen
DE60143095D1 (de) Trokar und trokarsystem
NO20040246L (no) TACI'er- og BR3-polypeptider og anvendelser derav
NO20030916D0 (no) Selektive cykliske peptider
DE60116678D1 (de) Polyarylen Kopolymer und Protonen leitende Membran
DE69900492T2 (de) Grosse kombinierte Breitband und Schmalband Vermittlungsstelle
DE60125406D1 (de) Hydrophilierte membran und hydrophilierungsverfahren dafür
ATE340158T1 (de) Pyrrolcarboxamide und pyrrolcarbothioamide und deren agrochemische verwendungen
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
DK1746375T3 (da) Oxygendrevet forbrændingssystem og anvendelser deraf
DE60203269D1 (de) Asymmetrische membran
DE60134026D1 (de) Bildanzeigeelement und bildanzeigeeinrichtung
DE60119245D1 (de) Kabelwegklemme und Verfahrensanwendung
DE60009803D1 (de) Mehrrichtungsschalter und Betätigungsvorrichtung
DE69911579D1 (de) Antimikrobielle peptide
DE60110683D1 (de) IgE-abhängiger histamin-freisetzender Faktor Rezeptor, bindende Peptide, dafür kodierende Nukleinsäuren und ihre Verwendungen
DE60208729D1 (de) Selbstausrichtendes und rastendes Befestigungselement
DE60115156D1 (de) Bipolare membran
DE60122873D1 (de) Therapeutische porenbildende peptide
DE60201244D1 (de) Polymermodifizierte Gipsmembran und deren Verwendung
SI1462455T1 (sl) Ser-Ser-Ser-Arg Peptid in zdravilna uporaba le-tega
NO20040880L (no) Casein avledete peptider og anvendelser derav i terapi.
DE69925120D1 (de) Molekulares stäbchen und dessen anwendungen
DE69816241D1 (de) Aktivierte peptide und konjugate
ATE426035T1 (de) Neue expressionsvektoren und deren verwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee